SynthesisBlood advances2026
Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.
Synthesis in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractWe conducted a pooled analysis to evaluate the effectiveness of hydroxyurea (HU), chronic blood transfusion (CBT), myeloablative allogeneic hematopoietic stem cell transplant (HCT) with a matched related donor, and revascularization surgery (RVS) in children with sickle cell anemia (SCA). We compared the interventions with no therapy for primary and secondary stroke prevention. The Medline and EMBASE databases were searched for articles that included ≥6 patients published before January 2025. Four reviewers reviewed all studies to arrive at a consensus assessment. The stroke rates (per 100 person-year) for primary stroke prevention in children with transcranial Doppler measurement ≥200 cm/s were as follows: no therapy, 10.7; after initial HU, 1.0; and after initial CBT, 1.0. The stroke recurrence rates for secondary stroke prevention per 100 person-years were 19.6 after no therapy, 3.5 after initial HU, 2.7 after initial CBT, 1.0 after HCT, and 3.3 after RVS. Neither the HCT nor the RVS study adjusted for the time-dependent stroke recurrence rate, resulting in an overestimation of their therapeutic benefit compared to the stroke recurrence rates before the intervention. In low- and middle-income countries (LMICs), where ∼99% of all children with SCA are born, the stroke recurrence rate in untreated children in the first year was 36.4 to 51.4 strokes per 100 person-years, in 2 studies; in the only randomized controlled trial for secondary stroke prevention with initial HU (SPRING trial n = 101), 38% (5 of 13) of the deaths occurred within the first year. For children in LMICs where local HU costs <$0.20 per day, HU is a practical, inexpensive option for primary and secondary stroke prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.